Skip to content

Efficacy of Jianpi Qushi Huatan Decoction in the Treatment of Polycystic Ovary Syndrome

Efficacy of Jianpi Qushi Huatan Decoction in the Treatment of Polycystic Ovary Syndrome: A Randomized Double-blind Placebo-controlled Trial

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05976295
Enrollment
68
Registered
2023-08-04
Start date
2023-08-31
Completion date
2025-12-01
Last updated
2023-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

Polycystic ovary syndrome (PCOS) is a common reproductive disease associated with endocrine and metabolic disorders. Some studies have shown that Chinese herbal medicine is beneficial for PCOS, but the efficacy of Chinese herbal medicine in the treatment of PCOS is not clear, because the quantity of pre-clinical data was limited and the quality of clinical evidence was variable. Therefore, this randomized double-blind placebo-controlled trial aim to evaluate the efficacy of Chinese herbal medicine (Jianpi Qushi Huatan Decoction) in women with PCOS.

Interventions

DRUGJianpi Qushi Huatan Decoction

The treatment group will receive the Jianpi Qushi Huatan Decoction (consisting of Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii, among others). Subjects will take the medication from the first day of inclusion, dissolving and consuming one packet twice a day (morning and evening) for a total of three months.

DRUGPlacebo

The control group will receive a placebo treatment.

Sponsors

Jiangxi University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. The diagnosis of PCOS is based on the Rotterdam criteria. 2. Meet the syndrome differentiation standard of spleen deficiency and phlegm-dampness in TCM theory. 3. women aged 18-40 years without fertility requirements. 4. A willingness to undergo this treatment plan.

Exclusion criteria

1. Hyperprolactinemia (2 times serum prolactin levels of more than 25 ng/ml at least one week apart). 2. Diminished ovarian reserve, FSH (follicle-stimulating hormone) level more than 10 IU/L. 3. Abnormal thyroid function, TSH (thyroid stimulating hormone) level less than 0.2 mIU/mL or more than 5.5 mIU/mL. 4. Suspected Cushing's syndrome. 5. Adrenal or ovarian tumors secreting androgen. 6. Poorly controlled type II diabetes. 7. Pregnancy or lactation. 8. Hypertensive patients with poorly controlled blood pressure (a systolic blood pressure more than 160 mmHg or a diastolic blood pressure more than 100 mmHg). 9. Those who had taken hormones or other drugs during the previous 3 months. 10. Acute heart, liver, kidney or blood diseases.

Design outcomes

Primary

MeasureTime frameDescription
Ovulation rate3 monthsOvulation rate in each group during the study period.

Countries

China

Contacts

Primary ContactLiang Ruining
jack169@sina.com0086-0791-88385243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026